Publications by authors named "Ming-Yao Lai"
Article Synopsis
- Epithelioid glioblastoma (Ep-GBM) is a rare and aggressive brain tumor variant, with a high recurrence rate and poor prognosis; there’s currently no established standard treatment for it.
- In a study of 58 Ep-GBM cases, common symptoms included headaches and dizziness, and the median survival rates were 12.7 months for progression-free survival and 29.1 months overall; reoperation after recurrence notably improved survival time.
- Key factors influencing survival included tumor spread before initial surgery, the number of adjuvant temozolomide cycles received, and radiotherapy; extending the Stupp regimen with more temozolomide cycles could enhance outcomes for patients.
Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. However, the efficacy and optimal dosage of osimertinib in the treatment of NSCLC patients with LM who harbor uncommon EGFR mutations have yet to be fully investigated.
View Article and Find Full Text PDFBackground: Despite evidence that a greater extent of resection (EOR) improves survival, the role of extended resection based on magnetic resonance imaging (MRI) fluid-attenuated inversion recovery (FLAIR) in the prognosis of glioblastoma (GBM) remains controversial. This study aims to investigate the role of additional resection of FLAIR-detected abnormalities and its influence on clinical outcomes of patients with GBM.
Methods: Forty-six patients with newly diagnosed GBM involving eloquent brain areas were included.
Objective: We retrospectively studied the efficacy of bevacizumab as salvage therapy for recurrent malignant glioma with a focus on the overall survival (OS).
Methods: Patients who received a therapy other than surgery for recurrent malignant glioma were included. Efficacy was evaluated using MRI.